Ranbaxy debuts generic Femara in UK, France and Romania; FDA OKs Zydus plant

26 July 2011

India’s largest drugmaker, Ranbaxy Laboratories (RANB: BO) which is 64% owned by Japan’s Daiichi Sankyo (TYO: 4568), yesterday announced the launch of letrozole tablets 2.5mg in the UK, Romania and France.

Letrozole is the bioequivalent of Swiss pharmaceutical major Novartis’ (NOVN: VX) breast cancer drug Femara, which last year generated sales of $58 million in the UK, $95 million in France and $5.5 million un Romania, Ranbaxy noted.

Commenting on the launch, Debashis Dasgupta, regional director of Ranbaxy, Europe, said: "We are pleased to introduce letrozole at the earliest available opportunity in UK, Romania and France with a view to broadening access to medication. The product will be offered through pharmacies, retail and wholesale stores with immediate effect and will benefit the health care system in these European Union markets."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK